QDEL Earnings Prediction
The chart below shows how QDEL performed 10 days before and after its earnings report, based on data from the past quarters. Typically, QDEL sees a +1.54% change in stock price 10 days leading up to the earnings, and a -3.12% change 10 days following the report. On the earnings day itself, the stock moves by -1.95%. This data can give you a slight idea of what to expect for the next quarter's release.
QDEL Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
707.80M
-4.69%
-2.65%
Gross Margin
39.30%
-11.59%
-4.87%
Operating Margin
4.83%
-60.25%
-32.16%
Net Margin
-21.67%
-2405.32%
690.88%
EPS
-2.28
-2380.00%
660.00%
No Data Available
QDEL Earnings Analysis
QuidelOrtho Corp Corporation (QDEL.O) Earnings Conference Call
Positive
Full Year Revenue Performance: Total reported revenue for the full year 2024 was $2,800,000,000, including $2,300,000,000 in non-respiratory revenue, reflecting a solid performance in line with expectations.
Adjusted EBITDA Performance: Adjusted EBITDA for the fourth quarter of 2024 was $150,000,000, representing a 21% adjusted EBITDA margin, showcasing effective cost management and operational efficiency.
Labs Business Growth: The labs business achieved a growth of 4% on a reported and constant currency basis, excluding COVID and non-core revenue, highlighting its stable and predictable business model.
Strong Profitability Indicators: Adjusted diluted earnings per share for the full year 2024 was $1.85, indicating strong profitability despite challenges in respiratory revenue.
2025 Adjusted EBITDA Forecast: The company expects full year 2025 adjusted EBITDA between $575,000,000 and $615,000,000, equating to a 22% adjusted EBITDA margin, reflecting anticipated margin expansion and operational improvements.
Negative
Q4 Revenue Decline: Total reported revenue in Q4 was $788,000,000, which decreased by 4% year over year due to expected declines in COVID and flu testing revenues.
Q4 Adjusted EBITDA Decline: Adjusted EBITDA for Q4 2024 was $150,000,000, compared to $195,000,000 in the prior year period, reflecting lower revenue from respiratory tests, which are high-margin contributors.
Earnings Per Share Decline: Adjusted diluted earnings per share was $0.63, down from $1.17 in the prior year period, primarily due to higher respiratory revenue in the prior year and increased interest expense.
North America Revenue Decline: North America revenue declined by 11% compared to the prior year period, driven by anticipated declines in respiratory revenue and the winding down of the U.S. Donor Screening business.
Gross Profit Margin Decline: Fourth quarter adjusted gross profit margin was 47%, down from 52% in the prior year period, primarily due to higher COVID and flu sales in the prior year and bonus accruals in Q4 2024 that did not occur in Q4 2023.
QDEL FAQs
How does QDEL typically perform around its earnings report dates?
Is QuidelOrtho Corp (QDEL) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
QDEL Earning Call Sentiment
Earnings call transcript: Quidel Q4 2024 earnings beat, stock rises
QDEL.O
0.53%Positive
The earnings call reflects a mix of both positive and negative factors. Financial performance showed a decline in revenue and EPS, but future guidance is optimistic with expected revenue growth and improved EBITDA margins. The Q&A section revealed concerns about cash flow and pricing pressures, but management expressed confidence in mid-single-digit growth. The lack of a specific shareholder return plan and uncertainties around tariffs are negatives. Given the company's market cap and mixed signals, the stock price is likely to remain neutral, with minor fluctuations over the next two weeks.
